Alkem Laboratories Reports Strong Q3FY26 Results with 11% Revenue Growth
Alkem Laboratories delivered robust Q3FY26 performance with total revenue growing 10.7% to ₹37,368 million, driven by strong international sales growth of 26.6%. The company maintained healthy profitability with EBITDA of ₹8,280 million and net profit of ₹6,360 million, while declaring an interim dividend of ₹43 per share and announcing strategic acquisition of Swiss medical devices company Occlutech.
*this image is generated using AI for illustrative purposes only.
Alkem Laboratories has announced its Q3FY26 financial results, delivering robust performance with 11% revenue growth and declaring an interim dividend of ₹43 per share. The pharmaceutical company also revealed a strategic acquisition in the medical devices sector through its subsidiary Alkem MedTech.
Q3FY26 Financial Performance
The company delivered strong financial metrics across key parameters for the quarter ended December 31, 2025:
| Metric: | Q3FY26 | Q3FY25 | Growth (YoY) |
|---|---|---|---|
| Total Revenue: | ₹37,368 million | ₹33,743 million | +10.7% |
| EBITDA: | ₹8,280 million | ₹7,594 million | +9.0% |
| EBITDA Margin: | 22.2% | 22.5% | -30 bps |
| Net Profit: | ₹6,360 million | ₹6,258 million | +1.6% |
| PAT Margin: | 17.0% | 18.5% | -150 bps |
| EPS: | ₹53.19 | ₹52.34 | +1.6% |
R&D expenses for the quarter stood at ₹1,390 million, representing 3.7% of total revenue from operations compared to 3.9% in Q3FY25.
Business Segment Performance
Alkem's diversified revenue streams showed varied growth patterns across geographies:
| Business Segment: | Q3FY26 Revenue | Growth (YoY) | Contribution |
|---|---|---|---|
| India Sales: | ₹24,959 million | +5.5% | 67.2% |
| US Sales: | ₹7,533 million | +18.8% | 20.3% |
| Non-US International: | ₹4,624 million | +41.6% | 12.5% |
According to IQVIA data, the company registered 9.8% growth compared to the Indian Pharmaceutical Market growth of 10.9%. Alkem outperformed in the acute segment by 80 basis points and marginally outperformed in chronic category by 18 basis points.
Strategic Acquisition Announcement
Alkem announced the execution of a binding term sheet to acquire a majority stake in Occlutech Holding AG, a Switzerland-based global medical devices company specializing in minimally invasive cardiac implants. The acquisition will be made through Alkem's wholly-owned subsidiary Alkem MedTech.
Sandeep Singh, Managing Director, commented: "This acquisition holds strategic importance as we work towards establishing a global footprint in medical devices. Occlutech is the third-largest player globally in the minimally invasive cardiac implants segment."
Interim Dividend Declaration
The Board of Directors declared an interim dividend of ₹43 per equity share for financial year 2025-2026:
| Parameter: | Details |
|---|---|
| Dividend Amount: | ₹43 per share |
| Face Value: | ₹2 per share |
| Dividend Percentage: | 2150% |
| Record Date: | February 20, 2026 |
| Payment Date: | March 6, 2026 |
Exceptional Items Impact
The company reported exceptional items of ₹528 million for the quarter, primarily related to the Government of India's notification of four Labour Codes effective from November 21, 2025. This represents a preliminary assessment of the incremental impact based on available information.
Management Commentary
Dr. Vikas Gupta, CEO, expressed optimism about future prospects: "Looking ahead, the planned launch of our GLP-1 semaglutide in March 2026 is expected to be among our key growth drivers. Our focus remains on execution, strengthening our product portfolio, and building long-term competitiveness across markets."
Historical Stock Returns for Alkem Laboratories
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.79% | -0.44% | -1.00% | +4.19% | +18.83% | +87.55% |
15
